Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up:<p><strong>Earnings</strong>: <strong>GOGO</strong> +5.3%, <strong>LUK</strong> +3.0%.</p><p><strong>General news</strong>:</p><ul><li><strong>LJPC</strong> +40.2% (announces positive top-line results from athos-3 phase 3 study of LJPC-501; 'primary efficacy endpoint analysis highly statistically significant'),</li><li><strong>PIRS</strong> +17.2% (granted ASKA Pharma an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose Phase 2a study; co will receive an immediate option payment of $2.75 mln from ASKA),</li><li><strong>ATRS</strong> +12.0% (announces that the New Drug Application for QuickShot Testosterone has been accepted for standard review by the FDA),</li><li><strong>ACRX</strong> +8.3% (New Drug Application for DSUVIA accepted for filing; PDUFA date is October 12, 2017),</li><li><strong>FEYE</strong> +2.3% (still checking)</li></ul><p><strong>Analyst actions</strong>:</p><ul><li><strong>PTEN</strong> +3.4% (added to US 1 List at BofA/Merrill),</li></ul></td> </tr></table>"